Janus Henderson Group PLC Madrigal Pharmaceuticals, Inc. Transaction History

Janus Henderson Group PLC

$182 Billion
Q2 2024

A detailed history of Janus Henderson Group PLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 2,485,751 shares of MDGL stock, worth $580 Million. This represents 0.38% of its overall portfolio holdings.

Number of Shares

2,485,751

Previous 2,601,282 4.44%

Holding current value

$580 Million

Previous $695 Million 0.25%

% of portfolio

0.38%

Previous 0.39%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $22.3 Million - $33.7 Million	-115,531 Reduced 4.44%	2,485,751 $696 Million
Q1 2024 May 15, 2024	SELL	$171.37 - $283.23 $51.5 Million - $85.2 Million	-300,768 Reduced 10.36%	2,601,282 $695 Million
Q4 2023 Feb 14, 2024	SELL	$120.4 - $237.13 $16.9 Million - $33.3 Million	-140,611 Reduced 4.62%	2,902,050 $671 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $228 Million - $352 Million	1,558,535 Added 105.01%	3,042,661 $444 Million
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $226 Million - $346 Million	1,108,452 Added 295.06%	1,484,126 $343 Million
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $44.6 Million - $59.3 Million	193,026 Added 105.68%	375,674 $91 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $5.62 Million - $28.5 Million	96,265 Added 111.44%	182,648 $53 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $5.23 Million - $6.87 Million	86,383 New	86,383 $5.61 Million
Q4 2018 Feb 06, 2019	SELL	$94.77 - $215.54 $127,276 - $289,470	-1,343 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$207.3 - $300.31 $94,114 - $136,340	454 Added 51.07%	1,343 $288,000
Q2 2018 Aug 10, 2018	BUY	$101.55 - $313.9 $90,277 - $279,057	889 New	889 $249,000

Others Institutions Holding MDGL

# of Institutions

297

Shares Held

22M

Call Options Held

757K

Put Options Held

370K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $3.99B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Madrigal Pharmaceuticals, Inc. Transaction History